|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,475 |
$2,347,413.75 |
6.93% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
41,733 |
$2,343,725.28 |
6.92% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
21,021 |
$2,341,318.98 |
6.91% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
10,477 |
$2,318,769.64 |
6.84% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
11,216 |
$2,260,584.80 |
6.67% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
87,169 |
$1,496,691.73 |
4.42% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,784 |
$1,312,364.80 |
3.87% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
47,068 |
$1,208,706.24 |
3.57% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,665 |
$1,190,291.85 |
3.51% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,738 |
$1,147,561.54 |
3.39% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,620 |
$1,126,128.40 |
3.32% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,353 |
$1,112,190.10 |
3.28% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,920 |
$1,084,684.80 |
3.20% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,678 |
$1,042,764.70 |
3.08% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,943 |
$890,289.97 |
2.63% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
9,927 |
$822,253.41 |
2.43% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
8,062 |
$794,590.72 |
2.34% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
4,308 |
$611,219.04 |
1.80% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
12,111 |
$583,265.76 |
1.72% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
6,420 |
$473,089.80 |
1.40% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
3,099 |
$471,822.75 |
1.39% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,505 |
$444,938.10 |
1.31% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
1,019 |
$432,056.00 |
1.28% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
7,443 |
$402,368.58 |
1.19% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,896 |
$378,051.52 |
1.12% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
9,873 |
$345,456.27 |
1.02% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
4,162 |
$312,337.30 |
0.92% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
12,871 |
$304,399.15 |
0.90% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
6,008 |
$255,940.80 |
0.76% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,948 |
$254,931.28 |
0.75% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
7,756 |
$241,599.40 |
0.71% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
8,787 |
$222,838.32 |
0.66% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
3,076 |
$223,594.44 |
0.66% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,815 |
$216,882.75 |
0.64% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,940 |
$207,890.40 |
0.61% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
15,297 |
$201,920.40 |
0.60% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
649 |
$198,405.79 |
0.59% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
902 |
$199,711.82 |
0.59% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,944 |
$193,155.84 |
0.57% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,906 |
$182,404.20 |
0.54% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,341 |
$181,583.35 |
0.54% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
6,185 |
$176,643.60 |
0.52% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,960 |
$168,716.80 |
0.50% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
3,271 |
$168,554.63 |
0.50% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
7,765 |
$167,724.00 |
0.49% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,205 |
$166,940.55 |
0.49% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
7,288 |
$163,251.20 |
0.48% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
538 |
$158,736.90 |
0.47% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,371 |
$145,128.91 |
0.43% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
6,637 |
$140,505.29 |
0.41% |
| US Dollar |
$USD |
|
Other |
49,444 |
$49,444.18 |
0.15% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|